Anatomic Stage IV Breast Cancer AJCC v8

Oncology·MeSH: Triple Negative Breast Neoplasms

Prevalence

287.0 / 100K

Incidence

128.0 / 100K/yr

29 drugs in development·4 companies·21 clinical trials

Drug Pipeline by Phase

Phase 3(7)

Drug	Company
cyclin-dependent kinase 4 inhibitor	GH Research PLC (GHRS)
cyclin-dependent kinase 6 inhibitor	GH Research PLC (GHRS)
Gardasill 9™ vaccine	UNITED THERAPEUTICS Corp (UTHR)
her2-targeted therapy	GH Research PLC (GHRS)
hormone therapy	GH Research PLC (GHRS)
pertuzumab	GH Research PLC (GHRS)
taxane compound	GH Research PLC (GHRS)

Phase 2(15)

Drug	Company
Anti-CD40 Agonist Monoclonal Antibody CDX-1140	UNITED THERAPEUTICS Corp (UTHR)
Anti-HER2/HER3 Dendritic Cell Vaccine	UNITED THERAPEUTICS Corp (UTHR)
Anti-PD-1 monoclonal antibody	UNITED THERAPEUTICS Corp (UTHR)
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine	UNITED THERAPEUTICS Corp (UTHR)
Dendritic Cell Vaccine	UNITED THERAPEUTICS Corp (UTHR)
Immune Checkpoint Inhibitor	ENANTA PHARMACEUTICALS INC (ENTA)
Personalized Synthetic Long Peptide Vaccine	ENANTA PHARMACEUTICALS INC (ENTA)
Poly ICLC	ENANTA PHARMACEUTICALS INC (ENTA)
pTVG-HP DNA vaccine	UNITED THERAPEUTICS Corp (UTHR)
sacituzumab govitecan	GH Research PLC (GHRS)
Sacituzumab Govitecan	ENANTA PHARMACEUTICALS INC (ENTA)
Smallpox and Mpox Vaccine	UNITED THERAPEUTICS Corp (UTHR)
Tremelimumab	ADMA BIOLOGICS, INC. (ADMA)
Tremelimumab	ENANTA PHARMACEUTICALS INC (ENTA)
WOKVAC Vaccine	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(2)

Drug	Company
Lm-GUCY2C vaccine	UNITED THERAPEUTICS Corp (UTHR)
Mammaglobin-A DNA Vaccine	UNITED THERAPEUTICS Corp (UTHR)

Early Phase 1(1)

Drug	Company
C-peptide	ENANTA PHARMACEUTICALS INC (ENTA)

N/A(1)

Drug	Company
Anti-Hypertensive medications	UNITED THERAPEUTICS Corp (UTHR)

Phase 4(3)

Drug	Company
Ad5.F35-hGUCY2C-PADRE vaccine	UNITED THERAPEUTICS Corp (UTHR)
DC1 Vaccine	UNITED THERAPEUTICS Corp (UTHR)
rF1V vaccine	UNITED THERAPEUTICS Corp (UTHR)

BioSniper tracks 29 drugs in development for Anatomic Stage IV Breast Cancer AJCC v8 across 4 companies.

There are 21 clinical trials targeting Anatomic Stage IV Breast Cancer AJCC v8 tracked by BioSniper.

The estimated prevalence of Anatomic Stage IV Breast Cancer AJCC v8 is approximately 287.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.